Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tambo Willians, Powell Keren, Wadolowski Steven, Unadkat Prashin, Chang Eric H, LeDoux Christopher, Sciubba Daniel, Wang Ping, Huerta Patricio, Li Chunyan
Аннотация
INTRODUCTION: Neuropeptide dysregulation and microvascular injury are involved in pathogenesis of vascular cognitive impairment (VCI); however, the underlying etiology of this pathological axis remains unclear.
METHODS: We investigated pathological mediators across varying severities of VCI in a rat model of chronic cerebral hypoperfusion (CCH). Proteomic analysis guided the evaluation of neuropeptide and non-neuropeptide markers associated with vascular and non-vascular dysfunction, which were correlated with cognitive function to determine their role in VCI.
RESULTS: Proteomic analysis revealed vasomotor dysfunction as the primary pathological pathway in VCI. Microvascular vasoconstriction was the earliest and most persistent event, initiating a cascade of both microvascular and non-vascular dysfunction. Dysregulation of vasoactive neuropeptides was identified as the key driver of this process. Calcitonin gene-related peptide (CGRP) supplementation effectively prevented vasoconstriction, and improved cognitive function in CCH.
DISCUSSION: This study suggests dysregulation of vasoactive neuropeptides plays a central role in CCH pathomechanism, with microvascular vasoconstriction acting as the primary mediator.
HIGHLIGHTS: Neuropeptides are the primary drivers of dominant pathomechanisms underlying chronic cerebral hypoperfusion (CCH). Early vasoactive neuropeptide dysregulation is a key driver of cognitive decline. Microvascular dysfunction precedes classical non-vascular pathologies in CCH. Capillary constriction precedes and drives amyloid accumulation in CCH. CGRP mitigates microvascular constriction, enhancing cognitive function in VCI.
METHODS: We investigated pathological mediators across varying severities of VCI in a rat model of chronic cerebral hypoperfusion (CCH). Proteomic analysis guided the evaluation of neuropeptide and non-neuropeptide markers associated with vascular and non-vascular dysfunction, which were correlated with cognitive function to determine their role in VCI.
RESULTS: Proteomic analysis revealed vasomotor dysfunction as the primary pathological pathway in VCI. Microvascular vasoconstriction was the earliest and most persistent event, initiating a cascade of both microvascular and non-vascular dysfunction. Dysregulation of vasoactive neuropeptides was identified as the key driver of this process. Calcitonin gene-related peptide (CGRP) supplementation effectively prevented vasoconstriction, and improved cognitive function in CCH.
DISCUSSION: This study suggests dysregulation of vasoactive neuropeptides plays a central role in CCH pathomechanism, with microvascular vasoconstriction acting as the primary mediator.
HIGHLIGHTS: Neuropeptides are the primary drivers of dominant pathomechanisms underlying chronic cerebral hypoperfusion (CCH). Early vasoactive neuropeptide dysregulation is a key driver of cognitive decline. Microvascular dysfunction precedes classical non-vascular pathologies in CCH. Capillary constriction precedes and drives amyloid accumulation in CCH. CGRP mitigates microvascular constriction, enhancing cognitive function in VCI.